The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol

Pediatric Blood and Cancer

Volumn 61, Issue 4, 2014, Pages 653-658

  Clemmensen, Kim K B ^a   Christensen, Regitse H ^a   Shabaneh, Diana N ^a   Harila Saari, Arja ^b   Heyman, Mats ^c   Jonsson, Olafur G ^d   Wesenberg, Finn ^e   Rosthøj, Susanne ^f   Schmiegelow, Kjeld ^a,g  

^a University of Copenhagen   (Denmark)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

6 mercaptopurine; Acute lymphoblastic leukemia; Child; Circadian rhythm; Methotrexate

Indexed keywords

FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ARTICLE; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; ERYTHROCYTE; EVENING DOSAGE; EVENT FREE SURVIVAL; FEMALE; GENDER; HIGH RISK POPULATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ACUTE LYMPHOBLASTIC LEUKEMIA; CHILD; CIRCADIAN RHYTHM; METHOTREXATE;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CIRCADIAN RHYTHM; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84893443636     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24867     Document Type: Article

References (30)

1. Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010; 24:345-354.
2. Arico M, Baruchel A, Bertrand Y, et al. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29-30, 2005. Leukemia 2005; 19:1145-1152.
3. Toyoda Y, Manabe A, Tsuchida M, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000; 18:1508-1516.
4. Schmiegelow K, Heyman M, Kristinsson J, et al. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: Results from the NOPHO ALL-92 study. J Pediatr Hematol Oncol 2009; 31:385-392.
5. Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12 000 randomised children. Lancet 1996; 347:1783-1788.
6. Smaaland R, Sothern RB, Laerum OD, et al. Rhythms in human bone marrow and blood cells. Chronobiol Int 2002; 19:101-127.
7. Haus E. Chronobiology in the endocrine system. Adv Drug Deliv Rev 2007; 59:985-1014.
8. Levi F, Okyar A, Dulong S, et al. Circadian timing in cancer treatments. Ann Rev Pharmacol Toxicol 2010; 50:377-421.
9. Rivard G, Infante-Rivard C, Hoyoux C, et al. Maintenance chemotherapy for childhood acute lymphoblastic leukaemia: Better in the evening. Lancet 1985; 326:1264-1266.
10. Schmiegelow K, Glomstein A, Kristinsson J, et al. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO). J Pediatr Hematol Oncol 1997; 19:102-109.
11. Schmiegelow K, Bjork O, Glomstein A, et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21:1332-1339.
12. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000; 14:2267-2275.
13. Cleveland W, Grosse E, Hyu W. Local regression models. In: Chambers J, Hastie T, editors. Statistical models. London: S. Wadsworth & Brooks/Cole; 1992.
14. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73:13-22.
15. Andersen PK, Borgan Ø, Gill RD, et al. Statistical models based on counting processes. New York, NY: Springer Verlag; 1993.
16. Clayton D, Hills M. Statistical models in epidemiology. Oxford: Oxford Science Publications; 1993.
17. Cox DR. Regression models life-tables. J R Stat Soc Series B 1972; 34:187-220.
18. Schmiegelow K, Forestier E, Kristinsson J, et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: Results from the NOPHO ALL-92 study. Leukemia 2009; 23:557-564.
19. Martinussen T, Scheike TH. Dynamic regression models for survival data. New York: Springer Verlag; 2006.
20. Lin DY, Wei LJ, Ying Z. Model-checking techniques based on cumulative residuals. Biometrics 2002; 58:1-12.
21. PASW Statistics 18. USA, 2009.
22. Cary, SAS., NC, USA, 2011.
23. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
24. Rivard GE, Infante-Rivard C, Dresse MF, et al. Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: A long-term follow-up study of survival. Chronobiol Int 1993; 10:201-204.
25. Pinkerton CR, Welshman SG, Glasgow JF, et al. Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia? Lancet 1980; 2:944-946.
26. Riccardi RF, Balis FM, Ferrara PF, et al. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1986; 3:319-324.
27. Rivard GE, Lin KT, Leclerc JM, et al. Milk could decrease the bioavailability of 6-mercaptopurine. J Pediatr Hematol Oncol 1989; 11:402-406.
28. Lonnerholm GF, Kreuger AF, Lindstrom BF, et al. Oral mercaptopurine in childhood leukemia: Influence of food intake on bioavailability. J Pediatr Hematol Oncol 1989; 6:105-112.
29. Lafolie PF, Bjork OF, Hayder S, et al. Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia. Med Oncol Tumor Pharmacother 1989; 6:259-265.
30. Burton NK, Barnett MJ, Aherne GW, et al. The effect of food on the oral administration of 6-mercaptopurine. Cancer Chemother Pharmacol 1986; 18:90-91.